Plain-English translation of NCT07370207 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a phase 2 clinical trial testing , a new injectable medication designed to help people with chronic hepatitis B who have already been taking standard antiviral drugs. The study will compare two slightly different dosing schedules of the medication over 24 weeks to see which works better and is safer. Researchers want to understand whether this new treatment can help control the virus in people whose current medications have kept their virus levels very low.
Many people with chronic hepatitis B reach a point where standard antiviral medications stop the virus from replicating, but don't completely clear the infection from their body. This medication aims to help trigger the immune system to recognize and fight the hepatitis B virus more effectively, potentially moving patients closer to a cure or long-term remission.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive weekly injections of the medication under your skin for 24 weeks. Depending on which study arm you're assigned to, you'll receive either 2 or 3 extra loading doses in the first few weeks to get the medication into your system more quickly. You'll have regular visits to the clinic to receive your injections, have blood tests to monitor your liver health and virus levels, and check for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Australia
China
New Zealand
Singapore
South Korea